Odyssey Therapeutics, Inc. (ODTX) - Form 8-K Summary
Business Context and Reporting Period
Odyssey Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 4, 2026. The filing announces the Company's financial results for the three months ended June 30, 2026. The Company is designated as an emerging growth company.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the period ended June 30, 2026.
Material Changes
The filing text does not contain specific data regarding material changes in financial condition or operations compared to prior periods. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting its legal incorporation into other filings unless expressly referenced.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash burn figures.
- Verify the Company's cash runway and liquidity position as of June 30, 2026.
- Confirm any updates to clinical trial timelines or regulatory milestones mentioned in the press release.
- Check for any new debt financing or equity raises disclosed in the full press release.